Changes in the gut microbiome and metabolome in a rat model of pulmonary arterial hypertension. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Hong, Wei; Mo, Qiudi; Wang, Luyao; Peng, Fang; Zhou, Yuming; Zou, Weifeng; Sun, Ruiting; Liang, Chunxiao; Zheng, Mengning; Li, Haiqing; Zhao, Dongxing; Gao, Mi; Pu, Jinding; Li, Bing; Ran, Pixin; Peng, Gongyong
• Is Part Of: Bioengineered. Volume 12:Issue 1(2021)
• Page Start: 5173
• Page End: 5183
• Publication Date: 2021-01-01
• Subjects: Pulmonary arterial hypertension -- gut -- microbiome -- metabolome; Biomedical engineering -- Periodicals; Biotechnology -- Periodicals; Microbiology -- Periodicals; 660.6
• DOI: 10.1080/21655979.2021.1952365
• Languages: English
• ISSNs: 2165-5987

Abstract

ABSTRACT: The gut microbiota is widely considered to be involved in several diseases, including atherosclerosis, obesity, chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH). This study aimed to determine if changes in the gut microbiome and metabolome play a major role in the early pathogenesis of PAH. Male Wistar rats were injected with monocrotaline (MCT) (55 mg/kg) at day 1 and injected with calcium-sensing receptor (CaSR) antagonist NPS2143 (4.5 mg/kg/d) from days 1 to 21. Fecal samples were obtained. The gut microbiota and metabolome were analyzed by 16S rRNA gene sequencing and mass spectrometry-based analysis to investigate the effect of PAH in this rat model. MCT injection had a marked effect on the composition of the gut microbiota. This finding was further confirmed by metabolomic analysis with identification of several metabolites relevant to the gut microflora. However, NPS2143 partially abrogated this intestinal flora disorder and reversed fecal metabolite abnormalities. In conclusion, our study shows correlations between changes in the gut microbiome and the metabolome in PAH, which are affected by NPS2143. Graphical abstract: uf0001